- Home
- FOF vs MXCT Comparison
FOF vs MXCT Comparison
Compare FOF & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- MXCT
- Stock Information
- Founded
- FOF 2006
- MXCT 1999
- Country
- FOF United States
- MXCT United States
- Employees
- FOF N/A
- MXCT N/A
- Industry
- FOF Investment Managers
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FOF Finance
- MXCT Health Care
- Exchange
- FOF Nasdaq
- MXCT Nasdaq
- Market Cap
- FOF 357.1M
- MXCT 398.3M
- IPO Year
- FOF N/A
- MXCT 2021
- Fundamental
- Price
- FOF $13.03
- MXCT $3.45
- Analyst Decision
- FOF
- MXCT Strong Buy
- Analyst Count
- FOF 0
- MXCT 3
- Target Price
- FOF N/A
- MXCT $8.67
- AVG Volume (30 Days)
- FOF 58.7K
- MXCT 599.5K
- Earning Date
- FOF 01-01-0001
- MXCT 11-06-2024
- Dividend Yield
- FOF 9.07%
- MXCT N/A
- EPS Growth
- FOF N/A
- MXCT N/A
- EPS
- FOF N/A
- MXCT N/A
- Revenue
- FOF N/A
- MXCT $45,599,000.00
- Revenue This Year
- FOF N/A
- MXCT N/A
- Revenue Next Year
- FOF N/A
- MXCT $21.59
- P/E Ratio
- FOF N/A
- MXCT N/A
- Revenue Growth
- FOF N/A
- MXCT 19.85
- 52 Week Low
- FOF $9.59
- MXCT $3.17
- 52 Week High
- FOF $11.75
- MXCT $5.55
- Technical
- Relative Strength Index (RSI)
- FOF 55.94
- MXCT 44.48
- Support Level
- FOF $12.70
- MXCT $3.17
- Resistance Level
- FOF $12.84
- MXCT $3.61
- Average True Range (ATR)
- FOF 0.18
- MXCT 0.25
- MACD
- FOF -0.00
- MXCT -0.01
- Stochastic Oscillator
- FOF 61.59
- MXCT 28.93
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.